In 2023, the actual sold production of antisera and vaccines in France stood at X billion euros. From 2024 onwards, the forecasted values are expected to grow steadily, reaching 2.9145 billion euros by 2028. The year-on-year growth rate is approximately 2.38% between 2024 and 2028, with a compound annual growth rate (CAGR) of around 2.28% over the five-year period. This consistent growth trajectory suggests a robust demand outlook in the market.
Future trends to watch for include potential advancements in vaccine development technologies, changes in regulatory environments, and any emergent public health challenges which could spur demand further. Additionally, international competition and new market entrants may influence production dynamics in France.
